<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02550613</url>
  </required_header>
  <id_info>
    <org_study_id>201401081MIND</org_study_id>
    <nct_id>NCT02550613</nct_id>
  </id_info>
  <brief_title>Evaluation of Treatment Response With Integrated MRI/PET in Patients With Hepatocellular Carcinoma</brief_title>
  <official_title>Evaluation of Treatment Response With Integrated MRI/PET in Patients With Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the ability of integrated MRI/PET to detect and
      evaluate treatment outcome in HCC patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study using 18F-FDG PET and functional MRI (DCE-MRI, Diffusion-weighted MRI, MR
      spectroscopy).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The recurrence rate at 3 months after treatment</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The overall survival after treatment</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The imaging biomarkers determined by MR-PET</intervention_name>
    <description>The purpose of this study is to explore the ability of integrated MRI/PET to detect and evaluate treatment outcome in HCC patients. This study using 18F-FDG PET and functional MRI (DCE-MRI, Diffusion-weighted MRI, MR spectroscopy).</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        We will enroll 100 HCC patients who are admitted for curative or non-curative treatments,
        including operation, radiofrequency ablation, TACE, target therapy, chemotherapy, or
        radiotherapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Prior Informed Consent Form

          2. At least one measurable tumor, according to RECIST version 1.1.

          3. Age &gt; 20 years.

          4. ECOG performance status 0 or 1.

          5. Life expectancy &gt; 3 months.

          6. Confirmed Diagnosis of HCC

          7. Adequate renal function (Serum creatinine â‰¦ 1.5 x upper limit of normal).

        Exclusion Criteria:

          1. Age &lt;20 years old

          2. Pregnancy

          3. Contraindication for MRI: claustrophobia or MR non-compatible devices

          4. Contraindication for MR contrast medium: severe adverse reaction or impaired renal
             function (Cre &gt; 2.0)

          5. History of other malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bang-Bin Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medical Imaging, National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ting-Fang Shih, MD</last_name>
    <phone>+886-2-23123456</phone>
    <phone_ext>65568</phone_ext>
    <email>ttfshih@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ting-Fang Shih, MD</last_name>
      <phone>+886-2-23123456</phone>
      <phone_ext>65568</phone_ext>
      <email>ttfshih@ntu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2015</study_first_submitted>
  <study_first_submitted_qc>September 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2015</study_first_posted>
  <last_update_submitted>May 14, 2017</last_update_submitted>
  <last_update_submitted_qc>May 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MR/PET, hepatocellular carcinoma, HCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

